Although antiangiogenic drugs such as ramucirumab and apatinib have been approved for treating advanced or metastatic GC in China, showing potential to prolong overall patient survival, in clinical practice, these drugs are often used without considering the VEGF status (23–28). Here, VEGFA is linked to gastric cancer.